Student Well-Being

Firm Moves Closer To Brain-Imaging Test for ADHD

By Darcia Harris Bowman — March 28, 2001 2 min read

A Boston company is nearing the final phase of testing a diagnostic drug that could offer health-care providers a long-awaited medical test for attention deficit hyperactivity disorder.

Boston Life Sciences Inc. announced this month that its product Altropane was successful in identifying adults who had been clinically diagnosed with long- standing ADHD by mapping the level of certain chemicals in their brain.

ADHD is the most commonly diagnosed behavioral disorder in American children, affecting an estimated 2 million school-age youngsters, according to the National Institutes of Health. Characterized by hyperactivity, short attention spans, and impulsivity, the condition often interferes with a child’s education.

No biological test for diagnosing ADHD is currently available, a situation that some experts contend has led to the misdiagnosis and unnecessary medication of many children. Currently, psychiatrists often rely heavily on reports from parents and educators about children’s behavior in making a diagnosis.

Researchers working on the development of Altropane say their study has shown abnormally high levels of the neurotransmitter dopamine in the brains of people with ADHD, which means a medical diagnosis may not be far away.

“Because of the national controversy presently surrounding the confusion and inconsistencies in the clinical diagnosis of ADHD, and the growing concern over the abuse of stimulant medications by schoolchildren, we believe that the need for an objective, biologically based diagnosis for ADHD has never been greater, nor more urgent for society,” Marc Lanser, Boston Life Science’s chief scientific officer, said in a written statement.

Under guidelines set by the U.S. Food and Drug Administration, the company conducted the first test of its imaging product in 1999 on 10 adult volunteers, six with ADHD, and increased the number of test subjects to 40 for the second phase. The results of the first study were published in The Lancet, a London-based journal of medicine.

The third and final trial of Altropane is to begin this summer with 100 adult test subjects.

Once the testing is wrapped up, Boston Life Sciences will apply to the FDA for fast-track approval to market the product, said Maria Zapf, the company’s manager of corporate affairs.

“Hopefully, this kind of product will quell a little of the controversy over whether ADHD is an actual disorder,” Ms. Zapf said.


Coverage of research is underwritten in part by a grant from the Spencer Foundation.

Related Tags:

A version of this article appeared in the March 28, 2001 edition of Education Week as Firm Moves Closer To Brain-Imaging Test for ADHD

Events

Student Well-Being Webinar Boosting Teacher and Student Motivation During the Pandemic: What It Takes
Join Alyson Klein and her expert guests for practical tips and discussion on how to keep students and teachers motivated as the pandemic drags on.
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Student Well-Being Webinar
A Holistic Approach to Social-Emotional Learning
Register to learn about the components and benefits of holistically implemented SEL.
Content provided by Committee for Children
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Student Well-Being Webinar
How Principals Can Support Student Well-Being During COVID
Join this webinar for tips on how to support and prioritize student health and well-being during COVID.
Content provided by Unruly Studios

EdWeek Top School Jobs

Arizona School Data Analyst - (AZVA)
Arizona, United States
K12 Inc.
Software Engineer
Portland, OR, US
Northwest Evaluation Association
Proposal Writer
Portland, OR, US
Northwest Evaluation Association
CCLC Program Site Director
Thornton, CO, US
Adams 12 Five Star Schools

Read Next

Student Well-Being Fauci's Latest on Vaccines for Young Kids: Not Likely This Year
A COVID-19 vaccine probably won’t be ready for elementary students until 2022, said Dr. Anthony Fauci, walking back prior comments.
2 min read
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, listens as President Joe Biden visits the Viral Pathogenesis Laboratory at the National Institutes of Health on Feb. 11, 2021, in Bethesda, Md.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, listens as the president visits the National Institutes of Health on Feb. 11.
Evan Vucci/AP
Student Well-Being Opinion New Research Explains Why Confessions Are Convincing
Admitting mistakes makes you come across as knowledgeable—and it’s a good way to model intellectual humility.
Sam Maglio
2 min read
Images shows a stylized artistic landscape with soothing colors.
Getty
Student Well-Being Spotlight Spotlight on Forging Student Connections & Growth Mindsets
In this Spotlight, discover ways to foster a growth mindset to re-connect and engage with students.
Student Well-Being Fauci Says Young Kids Could Start Getting Vaccinated by September
A COVID-19 vaccine for children as young as 1st grade may be approved by next school year, said Fauci. But some public health experts aren't so sure.
5 min read
First grade teacher Bella Legault bends down to greet a nervous incoming student at Foundation Preparatory School in New Orleans on Monday, Oct. 12, 2020.
First grade teacher Bella Legault bends down to greet a nervous incoming student at Foundation Preparatory School in New Orleans on Oct. 12.
Chris Granger/The Times-Picayune/The New Orleans Advocate via AP